The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
Official Title: A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer
Study ID: NCT01597388
Brief Summary: The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
Detailed Description: A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination with Intramuscular (IM) Fulvestrant to Patients with Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Research Site, Sarasota, Florida, United States
Research Site, Detroit, Michigan, United States
Research Site, Oklahoma City, Oklahoma, United States
Research Site, Greenville, South Carolina, United States
Research Site, Nashville, Tennessee, United States